array(40) {
  [0]=>
  string(4) "1832"
  ["article_id"]=>
  string(4) "1832"
  [1]=>
  string(88) "Diesel exhaust filtered of its tiny particles may worsen allergy-induced lung impairment"
  ["article_title"]=>
  string(88) "Diesel exhaust filtered of its tiny particles may worsen allergy-induced lung impairment"
  [2]=>
  string(150) "Air pollution from diesel engines may worsen allergy-induced lung impairment more when tiny particles are filtered from the exhaust than when they are"
  ["short_description"]=>
  string(150) "Air pollution from diesel engines may worsen allergy-induced lung impairment more when tiny particles are filtered from the exhaust than when they are"
  [3]=>
  string(298) "Air pollution from diesel engines may worsen allergy-induced lung impairment more when tiny particles are filtered from the exhaust than when they are not, according to new research published online in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine. "
  ["description"]=>
  string(298) "Air pollution from diesel engines may worsen allergy-induced lung impairment more when tiny particles are filtered from the exhaust than when they are not, according to new research published online in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine. "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "29"
  ["rss_id"]=>
  string(2) "29"
  [14]=>
  string(62) "https://www.sciencedaily.com/releases/2019/04/190412085232.htm"
  ["blog_url"]=>
  string(62) "https://www.sciencedaily.com/releases/2019/04/190412085232.htm"
  [15]=>
  string(19) "2019-04-12 20:52:32"
  ["add_date"]=>
  string(19) "2019-04-12 20:52:32"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-04-15 14:58:48"
  ["create_at"]=>
  string(19) "2019-04-15 14:58:48"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "4539"
  ["article_id"]=>
  string(4) "4539"
  [1]=>
  string(10) "MedDev Day"
  ["article_title"]=>
  string(10) "MedDev Day"
  [2]=>
  string(153) "A full day conference and a pre-conference workshop on "How to write a Clinical Evaluation Report from MDR Perspective"&#nlSince the European U"
  ["short_description"]=>
  string(153) "A full day conference and a pre-conference workshop on "How to write a Clinical Evaluation Report from MDR Perspective"&#nlSince the European U"
  [3]=>
  string(512) "A full day conference and a pre-conference workshop on "How to write a Clinical Evaluation Report from MDR Perspective"&#nlSince the European Union Medical Devices Regulations 2017/745 (MDR) entered in force, economic operators have been having busy times in adapting their processes and documentation in order to ensure compliance to the MDR requirements by its date of application (DOA) in May 2020. For the economic operators the challenge of the MDR comes together with revisions of the clinical..."
  ["description"]=>
  string(512) "A full day conference and a pre-conference workshop on "How to write a Clinical Evaluation Report from MDR Perspective"&#nlSince the European Union Medical Devices Regulations 2017/745 (MDR) entered in force, economic operators have been having busy times in adapting their processes and documentation in order to ensure compliance to the MDR requirements by its date of application (DOA) in May 2020. For the economic operators the challenge of the MDR comes together with revisions of the clinical..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(42) "https://www.pharmiweb.com/event/meddev-day"
  ["blog_url"]=>
  string(42) "https://www.pharmiweb.com/event/meddev-day"
  [15]=>
  string(19) "2019-04-12 18:00:51"
  ["add_date"]=>
  string(19) "2019-04-12 18:00:51"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-09-14 14:32:21"
  ["create_at"]=>
  string(19) "2019-09-14 14:32:21"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2126"
  ["article_id"]=>
  string(4) "2126"
  [1]=>
  string(64) "Boston Tech Watch: Tufin, Facebook, RightHand, Diameter & Jebbit"
  ["article_title"]=>
  string(64) "Boston Tech Watch: Tufin, Facebook, RightHand, Diameter & Jebbit"
  [2]=>
  string(150) "[Updated 4/15/19, 10:50 AM. See below.] A cybersecurity IPO could raise up to $124 million for an Israeli-based company with its US headquarters in Bo"
  ["short_description"]=>
  string(150) "[Updated 4/15/19, 10:50 AM. See below.] A cybersecurity IPO could raise up to $124 million for an Israeli-based company with its US headquarters in Bo"
  [3]=>
  string(356) "[Updated 4/15/19, 10:50 AM. See below.] A cybersecurity IPO could raise up to $124 million for an Israeli-based company with its US headquarters in Boston. Facebook’s Boston office wants to map the world’s population in high def, starting with Africa. More venture cash is flowing into Bay State startups. Read all this and much more […]"
  ["description"]=>
  string(356) "[Updated 4/15/19, 10:50 AM. See below.] A cybersecurity IPO could raise up to $124 million for an Israeli-based company with its US headquarters in Boston. Facebook’s Boston office wants to map the world’s population in high def, starting with Africa. More venture cash is flowing into Bay State startups. Read all this and much more […]"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "37"
  ["rss_id"]=>
  string(2) "37"
  [14]=>
  string(62) "http://feedproxy.google.com/~r/XconomyHealthIT/~3/fEutkz8jZ-w/"
  ["blog_url"]=>
  string(62) "http://feedproxy.google.com/~r/XconomyHealthIT/~3/fEutkz8jZ-w/"
  [15]=>
  string(19) "2019-04-12 18:00:09"
  ["add_date"]=>
  string(19) "2019-04-12 18:00:09"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:41:33"
  ["create_at"]=>
  string(19) "2019-05-09 16:41:33"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2187"
  ["article_id"]=>
  string(4) "2187"
  [1]=>
  string(78) "Teva Canada announces the approval of Truxima, the first biosimilar to Rituxan"
  ["article_title"]=>
  string(78) "Teva Canada announces the approval of Truxima, the first biosimilar to Rituxan"
  [2]=>
  string(150) "Teva Canada Innovation, announced that Health Canada has granted a notice of compliance (NOC) for Truxima (rituximab). Truxima is the first biosimilar"
  ["short_description"]=>
  string(150) "Teva Canada Innovation, announced that Health Canada has granted a notice of compliance (NOC) for Truxima (rituximab). Truxima is the first biosimilar"
  [3]=>
  string(705) "Teva Canada Innovation, announced that Health Canada has granted a notice of compliance (NOC) for Truxima (rituximab). Truxima is the first biosimilar to Rituxan (rituximab) in Canada for the treatment of adult patients in: Non-Hodgkin’s Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL) and Rheumatoid Arthritis (RA). “Biosimilars are a new chapter in the therapeutic oncology setting in Canada and represent a growing focus for Teva since they will allow us to increase access to important therapeutic options,” said Christine Poulin, Senior […]"
  ["description"]=>
  string(705) "Teva Canada Innovation, announced that Health Canada has granted a notice of compliance (NOC) for Truxima (rituximab). Truxima is the first biosimilar to Rituxan (rituximab) in Canada for the treatment of adult patients in: Non-Hodgkin’s Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL) and Rheumatoid Arthritis (RA). “Biosimilars are a new chapter in the therapeutic oncology setting in Canada and represent a growing focus for Teva since they will allow us to increase access to important therapeutic options,” said Christine Poulin, Senior […]"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "43"
  ["rss_id"]=>
  string(2) "43"
  [14]=>
  string(61) "http://feedproxy.google.com/~r/BiosimilarNews/~3/zNkZOEF9RVA/"
  ["blog_url"]=>
  string(61) "http://feedproxy.google.com/~r/BiosimilarNews/~3/zNkZOEF9RVA/"
  [15]=>
  string(19) "2019-04-12 17:53:57"
  ["add_date"]=>
  string(19) "2019-04-12 17:53:57"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:41:41"
  ["create_at"]=>
  string(19) "2019-05-09 16:41:41"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2355"
  ["article_id"]=>
  string(4) "2355"
  [1]=>
  string(93) "&#nlUpdate of EU recommendations for 2019/2020 seasonal flu vaccine composition, , 12/04/2019"
  ["article_title"]=>
  string(93) "&#nlUpdate of EU recommendations for 2019/2020 seasonal flu vaccine composition, , 12/04/2019"
  [2]=>
  string(174) "&#nl&#nl          &#nl              EMA has issued an &#nl&#nl&#nl  update of the EU recommendations for the influenza virus strains&#nl&#nlthat vaccine manufacturers should "
  ["short_description"]=>
  string(174) "&#nl&#nl          &#nl              EMA has issued an &#nl&#nl&#nl  update of the EU recommendations for the influenza virus strains&#nl&#nlthat vaccine manufacturers should "
  [3]=>
  string(204) "&#nl&#nl          &#nl              EMA has issued an &#nl&#nl&#nl  update of the EU recommendations for the influenza virus strains&#nl&#nlthat vaccine manufacturers should include in vaccines for the..."
  ["description"]=>
  string(204) "&#nl&#nl          &#nl              EMA has issued an &#nl&#nl&#nl  update of the EU recommendations for the influenza virus strains&#nl&#nlthat vaccine manufacturers should include in vaccines for the..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "88"
  ["rss_id"]=>
  string(2) "88"
  [14]=>
  string(102) "
https://www.ema.europa.eu/en/news/update-eu-recommendations-20192020-seasonal-flu-vaccine-composition"
  ["blog_url"]=>
  string(102) "
https://www.ema.europa.eu/en/news/update-eu-recommendations-20192020-seasonal-flu-vaccine-composition"
  [15]=>
  string(19) "2019-04-12 16:55:00"
  ["add_date"]=>
  string(19) "2019-04-12 16:55:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:42:13"
  ["create_at"]=>
  string(19) "2019-05-09 16:42:13"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "4504"
  ["article_id"]=>
  string(4) "4504"
  [1]=>
  string(30) "European Epidemiological Forum"
  ["article_title"]=>
  string(30) "European Epidemiological Forum"
  [2]=>
  string(164) "New Approaches to Drugs Value Demonstration in the Age of Big Data: Anatomy of a Paradigm Shift&#nl“In God we trust. All others must bring data” &#nlW. "
  ["short_description"]=>
  string(164) "New Approaches to Drugs Value Demonstration in the Age of Big Data: Anatomy of a Paradigm Shift&#nl“In God we trust. All others must bring data” &#nlW. "
  [3]=>
  string(526) "New Approaches to Drugs Value Demonstration in the Age of Big Data: Anatomy of a Paradigm Shift&#nl“In God we trust. All others must bring data” &#nlW. Deming&#nl&#nl&#nlWith the development of advanced medical therapies, for targeted or orphan diseases, the need for data generation has never been more important. Payers, HTA bodies and Decision Makers increasingly need evidence beyond Randomized Clinical trials (RCT), an artificial if rigorous way to demonstrate causality. Hence the efforts to collect data..."
  ["description"]=>
  string(526) "New Approaches to Drugs Value Demonstration in the Age of Big Data: Anatomy of a Paradigm Shift&#nl“In God we trust. All others must bring data” &#nlW. Deming&#nl&#nl&#nlWith the development of advanced medical therapies, for targeted or orphan diseases, the need for data generation has never been more important. Payers, HTA bodies and Decision Makers increasingly need evidence beyond Randomized Clinical trials (RCT), an artificial if rigorous way to demonstrate causality. Hence the efforts to collect data..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(62) "https://www.pharmiweb.com/event/european-epidemiological-forum"
  ["blog_url"]=>
  string(62) "https://www.pharmiweb.com/event/european-epidemiological-forum"
  [15]=>
  string(19) "2019-04-12 16:53:27"
  ["add_date"]=>
  string(19) "2019-04-12 16:53:27"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-09-14 14:32:21"
  ["create_at"]=>
  string(19) "2019-09-14 14:32:21"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1996"
  ["article_id"]=>
  string(4) "1996"
  [1]=>
  string(110) "Albireo Announces FDA Clearance of IND to Commence Phase 2 Trial of Elobixibat for the Treatment of NAFLD/NASH"
  ["article_title"]=>
  string(110) "Albireo Announces FDA Clearance of IND to Commence Phase 2 Trial of Elobixibat for the Treatment of NAFLD/NASH"
  [2]=>
  string(150) "BOSTON, April 11, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing nov"
  ["short_description"]=>
  string(150) "BOSTON, April 11, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing nov"
  [3]=>
  string(249) "BOSTON, April 11, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that its Investigational New Drug application (IND) has..."
  ["description"]=>
  string(249) "BOSTON, April 11, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that its Investigational New Drug application (IND) has..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(285) "https://www.drugs.com/clinical_trials/albireo-announces-fda-clearance-ind-commence-phase-2-trial-elobixibat-nafld-nash-18127.html?utm_source=ddc&utm_medium=rss&utm_campaign=Albireo+Announces+FDA+Clearance+of+IND+to+Commence+Phase+2+Trial+of+Elobixibat+for+the+Treatment+of+NAFLD%2FNASH"
  ["blog_url"]=>
  string(285) "https://www.drugs.com/clinical_trials/albireo-announces-fda-clearance-ind-commence-phase-2-trial-elobixibat-nafld-nash-18127.html?utm_source=ddc&utm_medium=rss&utm_campaign=Albireo+Announces+FDA+Clearance+of+IND+to+Commence+Phase+2+Trial+of+Elobixibat+for+the+Treatment+of+NAFLD%2FNASH"
  [15]=>
  string(19) "2019-04-12 07:04:23"
  ["add_date"]=>
  string(19) "2019-04-12 07:04:23"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:57"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:57"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1833"
  ["article_id"]=>
  string(4) "1833"
  [1]=>
  string(86) "Itchy skin affects the health and quality of life of many patients with kidney disease"
  ["article_title"]=>
  string(86) "Itchy skin affects the health and quality of life of many patients with kidney disease"
  [2]=>
  string(150) "New research reveals that pruritus, or itchy skin, affects a substantial percentage of patients with chronic kidney disease (CKD). The study also indi"
  ["short_description"]=>
  string(150) "New research reveals that pruritus, or itchy skin, affects a substantial percentage of patients with chronic kidney disease (CKD). The study also indi"
  [3]=>
  string(280) "New research reveals that pruritus, or itchy skin, affects a substantial percentage of patients with chronic kidney disease (CKD). The study also indicates which patients are more likely to experience pruritus, and demonstrates that pruritus may affect quality of life and sleep. "
  ["description"]=>
  string(280) "New research reveals that pruritus, or itchy skin, affects a substantial percentage of patients with chronic kidney disease (CKD). The study also indicates which patients are more likely to experience pruritus, and demonstrates that pruritus may affect quality of life and sleep. "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "29"
  ["rss_id"]=>
  string(2) "29"
  [14]=>
  string(62) "https://www.sciencedaily.com/releases/2019/04/190411172551.htm"
  ["blog_url"]=>
  string(62) "https://www.sciencedaily.com/releases/2019/04/190411172551.htm"
  [15]=>
  string(19) "2019-04-12 05:25:51"
  ["add_date"]=>
  string(19) "2019-04-12 05:25:51"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-04-15 14:58:48"
  ["create_at"]=>
  string(19) "2019-04-15 14:58:48"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2127"
  ["article_id"]=>
  string(4) "2127"
  [1]=>
  string(47) "WI Watchlist: DotCom Therapy, Nordic, UWM, Epic"
  ["article_title"]=>
  string(47) "WI Watchlist: DotCom Therapy, Nordic, UWM, Epic"
  [2]=>
  string(150) "It’s time to catch up on recent happenings in Wisconsin’s innovation community: —Madison-based telemedicine startup DotCom Therapy n"
  ["short_description"]=>
  string(150) "It’s time to catch up on recent happenings in Wisconsin’s innovation community: —Madison-based telemedicine startup DotCom Therapy n"
  [3]=>
  string(398) "It’s time to catch up on recent happenings in Wisconsin’s innovation community: —Madison-based telemedicine startup DotCom Therapy named Sanaz Cordes as its chief executive and said it raised an undisclosed amount of funding from HealthX Ventures, a local venture firm that backs healthtech companies. Cordes is a physician and former chief operations officer of another […]"
  ["description"]=>
  string(398) "It’s time to catch up on recent happenings in Wisconsin’s innovation community: —Madison-based telemedicine startup DotCom Therapy named Sanaz Cordes as its chief executive and said it raised an undisclosed amount of funding from HealthX Ventures, a local venture firm that backs healthtech companies. Cordes is a physician and former chief operations officer of another […]"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "37"
  ["rss_id"]=>
  string(2) "37"
  [14]=>
  string(62) "http://feedproxy.google.com/~r/XconomyHealthIT/~3/CKYcqFLBAqg/"
  ["blog_url"]=>
  string(62) "http://feedproxy.google.com/~r/XconomyHealthIT/~3/CKYcqFLBAqg/"
  [15]=>
  string(19) "2019-04-12 04:51:43"
  ["add_date"]=>
  string(19) "2019-04-12 04:51:43"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:41:33"
  ["create_at"]=>
  string(19) "2019-05-09 16:41:33"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1997"
  ["article_id"]=>
  string(4) "1997"
  [1]=>
  string(84) "FDA Orders Important Safety Labeling Changes for Addyi Regarding Alcohol Consumption"
  ["article_title"]=>
  string(84) "FDA Orders Important Safety Labeling Changes for Addyi Regarding Alcohol Consumption"
  [2]=>
  string(150) "April 11, 2019 -- The U.S. Food and Drug Administration today issued a safety labeling change order to Sprout Pharmaceuticals for their drug, Addyi (f"
  ["short_description"]=>
  string(150) "April 11, 2019 -- The U.S. Food and Drug Administration today issued a safety labeling change order to Sprout Pharmaceuticals for their drug, Addyi (f"
  [3]=>
  string(251) "April 11, 2019 -- The U.S. Food and Drug Administration today issued a safety labeling change order to Sprout Pharmaceuticals for their drug, Addyi (flibanserin), that requires the company to revise important safety information that women and their..."
  ["description"]=>
  string(251) "April 11, 2019 -- The U.S. Food and Drug Administration today issued a safety labeling change order to Sprout Pharmaceuticals for their drug, Addyi (flibanserin), that requires the company to revise important safety information that women and their..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(257) "https://www.drugs.com/clinical_trials/fda-orders-important-safety-labeling-changes-addyi-regarding-alcohol-consumption-18120.html?utm_source=ddc&utm_medium=rss&utm_campaign=FDA+Orders+Important+Safety+Labeling+Changes+for+Addyi+Regarding+Alcohol+Consumption"
  ["blog_url"]=>
  string(257) "https://www.drugs.com/clinical_trials/fda-orders-important-safety-labeling-changes-addyi-regarding-alcohol-consumption-18120.html?utm_source=ddc&utm_medium=rss&utm_campaign=FDA+Orders+Important+Safety+Labeling+Changes+for+Addyi+Regarding+Alcohol+Consumption"
  [15]=>
  string(19) "2019-04-12 04:04:55"
  ["add_date"]=>
  string(19) "2019-04-12 04:04:55"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:35:57"
  ["create_at"]=>
  string(19) "2019-05-09 16:35:57"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1834"
  ["article_id"]=>
  string(4) "1834"
  [1]=>
  string(81) "In mice, eliminating damaged mitochondria alleviates chronic inflammatory disease"
  ["article_title"]=>
  string(81) "In mice, eliminating damaged mitochondria alleviates chronic inflammatory disease"
  [2]=>
  string(150) "Treatment with a choline kinase inhibitor prompts immune cells to clear away damaged mitochondria, thus reducing NLRP3 inflammasome activation and pre"
  ["short_description"]=>
  string(150) "Treatment with a choline kinase inhibitor prompts immune cells to clear away damaged mitochondria, thus reducing NLRP3 inflammasome activation and pre"
  [3]=>
  string(172) "Treatment with a choline kinase inhibitor prompts immune cells to clear away damaged mitochondria, thus reducing NLRP3 inflammasome activation and preventing inflammation. "
  ["description"]=>
  string(172) "Treatment with a choline kinase inhibitor prompts immune cells to clear away damaged mitochondria, thus reducing NLRP3 inflammasome activation and preventing inflammation. "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "29"
  ["rss_id"]=>
  string(2) "29"
  [14]=>
  string(62) "https://www.sciencedaily.com/releases/2019/04/190411154722.htm"
  ["blog_url"]=>
  string(62) "https://www.sciencedaily.com/releases/2019/04/190411154722.htm"
  [15]=>
  string(19) "2019-04-12 03:47:22"
  ["add_date"]=>
  string(19) "2019-04-12 03:47:22"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-04-15 14:58:48"
  ["create_at"]=>
  string(19) "2019-04-15 14:58:48"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1835"
  ["article_id"]=>
  string(4) "1835"
  [1]=>
  string(83) "Longer neutrophil lifespan may contribute to HIV-associated intestinal inflammation"
  ["article_title"]=>
  string(83) "Longer neutrophil lifespan may contribute to HIV-associated intestinal inflammation"
  [2]=>
  string(150) "The increased survival of white blood cells called neutrophils is associated with alterations in the intestinal microbiome of HIV-infected individuals"
  ["short_description"]=>
  string(150) "The increased survival of white blood cells called neutrophils is associated with alterations in the intestinal microbiome of HIV-infected individuals"
  [3]=>
  string(178) "The increased survival of white blood cells called neutrophils is associated with alterations in the intestinal microbiome of HIV-infected individuals, according to a new study. "
  ["description"]=>
  string(178) "The increased survival of white blood cells called neutrophils is associated with alterations in the intestinal microbiome of HIV-infected individuals, according to a new study. "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "29"
  ["rss_id"]=>
  string(2) "29"
  [14]=>
  string(62) "https://www.sciencedaily.com/releases/2019/04/190411145150.htm"
  ["blog_url"]=>
  string(62) "https://www.sciencedaily.com/releases/2019/04/190411145150.htm"
  [15]=>
  string(19) "2019-04-12 02:51:50"
  ["add_date"]=>
  string(19) "2019-04-12 02:51:50"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-04-15 14:58:48"
  ["create_at"]=>
  string(19) "2019-04-15 14:58:48"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}